Otsuka's kidney disease drug shows over 50% reduction in protein in urine
Otsuka Announces FDA Acceptance And Priority Review Of BLA For Sibeprenlimab In Treatment Of Igan
RCS - Cambridge Isotope - Cambridge Isotope Laboratories Launches ISOLED-D
Brief: Otsuka Pharmaceutical - Us Subsidiary Has Opened New Facility In Ohio, Dedicated To Manufacturing Of Gummy Supplements
Table: Otsuka Holdings -Q1 group results (IFRS)
Otsuka Files Biologics License Application (BLA) For Sibeprenlimab In Treatment Of Immunoglobulin A Nephropathy
To Spend Up To 70 Billion Yen To Buy Back 2.23% Of Shares
Taiho Pharmaceutical To Acquire Next-Generation ADC Drug Discovery Company Araris Biotech
Table: Otsuka Holdings -2024 group results (IFRS)
Table: Otsuka Holdings -2024 group forecast(IFRS)
To Retire Treasury Shares Worth 1.04% Of Outstanding Stock On Dec. 9
Otsuka Pharmaceutical Factory, Inc. And Icu Medical Announce Establishment Of Joint Venture
Makoto Inoue To Become President, CEO From Jan 1, 2025
Table: Otsuka Holdings -9-MTH group results (IFRS)
Brief: Otsuka Holdings Announces Positive Interim Results From Phase 3 Trial Of Sibeprenlimab For Treatment Of Immunoglobulin A Nephropathy In Adults
Media: Otsuka is said to weigh sale of stake in medical device maker MicroPort Scientific - Bloomberg News
Obtains Additional Indication For Rexulti In Japan As An Adjunctive Treatment For Agitation Associated With Dementia Due To Alzheimer's Disease
India's Lupin slides as Otsuka appeals US ruling on drug
Deals of the day-Mergers and acquisitions